Last reviewed · How we verify
Apnea in the newborn — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Norgesic | caffeine | Hikma | Central Nervous System Stimulant [EPC] | Adenosine receptor A2a | 1948-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Apnea in the newborn
- Hikma · 1 drug in Apnea in the newborn
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Apnea in the newborn:
- Apnea in the newborn treatment updates — RSS
- Apnea in the newborn treatment updates — Atom
- Apnea in the newborn treatment updates — JSON
Cite this brief
Drug Landscape (2026). Apnea in the newborn — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/apnea-in-the-newborn. Accessed 2026-06-10.
Related
- Apnea in the newborn full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing